TERT and hepatocellular carcinoma: Conclusively, inhibitors targeting the TERT pathway have been studied in cellular and murine models of HCC (Fig. 4a); however, they have not yet undergone clinical trials for therapeutic evaluation, leading to elusive therapeutic effects.